Food Shouldn’t Hurt: Why Eupraxia Pharmaceuticals Is Building a More Precise EoE Investment Story -( $EPRX $MRNA $MRK $REGN $SNY $TAK $XBI ) by John F. Heerdink, Jr. 3 days ago Read more 🚀 Register to Join “Food Shouldn’t Hurt: EoE, Eupraxia, and a Promising New Treatment Approach” – (Friday, August 21 at 8:30am PT) by John F. Heerdink, Jr. 4 days ago Read more Tenon Medical’s Breakout Day Puts the SI-Joint Story on Wall Street’s Radar – ( $TNON ) by John F. Heerdink, Jr. 5 days ago Read more Amwell’s Quietly Compounding Digital-Care Story Is Getting Harder to Ignore -( $AMWL ) by John F. Heerdink, Jr. August 19, 2026 Read more Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA ) by John F. Heerdink, Jr. August 19, 2026 Read more Amylyx Ignites a New GLP-1 Investment Narrative as Clinical Data, Pharmacy Access and Diabetes Innovation Converge -( $AMLX $CVS $LLY $MODD $NVO ) by John F. Heerdink, Jr. August 18, 2026 Read more Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK ) by John F. Heerdink, Jr. August 17, 2026 Read more Heartflow’s AI-Cardiology Moment Arrives as Consumer Cyclicals Catch Their Breath -( $AMWL $HD $HTFL $LOW $TGT $WMT ) by John F. Heerdink, Jr. August 17, 2026 Read more What’s Up $DOCS?… Doximity’s AI Prescription Is Starting to Look Like a Platform Story by John F. Heerdink, Jr. August 15, 2026 Read more Fortell’s AI Hearing Aid Could Turn a Staid Medical-Device Category Into a Premium Technology Market -( $BLFY $GNNDY $GOOGL $NVDA $SONVY ) by John F. Heerdink, Jr. August 14, 2026 Read more Read more
Amwell’s Quietly Compounding Digital-Care Story Is Getting Harder to Ignore -( $AMWL )